Aclaris Therapeutics (ACRS) Stock Highlights

2.72 | -1.81%

2024-12-21 06:24:06

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Statistics

Range Today

2.71 2.9

Volume Today 1.16M

Range 1 Year

0.8 5.17

Volume 1 Year 357.96M

Range 3 Year

0.59 18.96

Volume 3 Year 884.9M

Range 10 Year

0.59 33.88

Volume 10 Year 1.76B

Highlights

Market Capitalization 188.35M (small)

Floating Shares 55.2M

Current Price 2.72

Price To Earnings -4.43

Price To Revenue 1.56

Price To Book 1.19

Earnings Per Share -0.56

Payout Ratio 0%

Performance

Latest -1.81%

1 Month -38.74%

3 Months +122.95%

6 Months +134.48%

1 Year +174.75%

3 Years -80.36%

5 Years +53.67%

10 Years -75.27%

Benchmarks

Market Capitalization

271 / 368

Gross Profits

207 / 278

Total Revenue

162 / 300

Total Rank

110 / 368

Free Cashflow

221 / 352

Performance 5 years

80 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.